Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lupin Pharmaceuticals has been cleared by the FDA to market the generic equivalent of Merck & Co.'s high cholesterol treatment Zocor, in 10mg, 20mg, 40mg and 80mg strengths.
Subscribe to our email newsletter
Vinita Gupta, president and managing director of Lupin, said: “We are delighted to receive final FDA approval for simvastatin tablets. The addition of generic Zocor complements Lupin’s commitment to bringing high-quality, low cost drug alternatives to the American public.”
Zocor, Merck’s statin for modifying cholesterol, achieved worldwide sales of $2.8 billion, a 36% decrease compared to the full year of 2005. Merck’s US marketing exclusivity for Zocor expired on June 23, 2006.
With this approval, Mumbai-based Lupin now has 21 abbreviated new drug applications approved by the US FDA.